BGB-A317-316
Recruiting
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
BeOne Study ID
BGB-A317-316
ClinicalTrials.gov ID
EudraCT or EUCT Number
2025-522862-58-00
Study Overview
Sex: All
Age: 18 Years / N/A
Accepts Healthy Volunteers? No
No Study Documents
Locations
Study Overview
Sex: All
Age: 18 Years / N/A
Accepts Healthy Volunteers? No
No Study Documents